

General information about company		
Scrip code*		524703
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE751D01014
Name of company		SANDU PHARMACEUTICALS LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2024
Date of end of financial year		31-03-2025
Date of board meeting when results were approved		28-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		17-05-2025
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Fourth quarter
Nature of report standalone or consolidated		Standalone
Whether results are audited or unaudited for the quarter ended		Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Audited
Segment Reporting		Single segment
Description of single segment		MANUFACTURE OF AYURVEDIC MEDICINE
Start date and time of board meeting		28-05-2025 15:00
End date and time of board meeting		28-05-2025 21:15
Whether cash flow statement is applicable on company		Yes
Type of cash flow statement		Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion
Whether the company has any related party?		Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?		Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public		NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.		NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		13-02-2025
Indicate Company website link for updated RPT policy of the Company		https://sandu.in/wp-content/uploads/2025/04/policy-on-materiality-and-dealing-with-Related-Party-Transaction-13.02.2025-1.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		3
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?		No Note: The Company has not defaulted on Loans and Debt Securities.

Financial Results – Ind-AS			
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period	01-01-2025	01-04-2024	
Date of end of reporting period	31-03-2025	31-03-2025	
Whether results are audited or unaudited	Audited	Audited	
Nature of report standalone or consolidated	Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	1406.92	6719.24
	Other income	6.93	16.75
	Total income	1413.85	6735.99
2	Expenses		
(a)	Cost of materials consumed	301.49	1011.98
(b)	Purchases of stock-in-trade	728.93	2318.45
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-452.56	-120.24
(d)	Employee benefit expense	282.74	1092.03
(e)	Finance costs	2.63	10.33
(f)	Depreciation, depletion and amortisation expense	14.81	67.06
(g)	Other Expenses		
1	Other Expenses	501.57	2140.8
	Total other expenses	501.57	2140.8
	Total expenses	1379.61	6520.41
3	Total profit before exceptional items and tax	34.24	215.58
4	Exceptional items	0	0
5	Total profit before tax	34.24	215.58
6	Tax expense		
7	Current tax	7.41	58.86
8	Deferred tax	-5.81	1.83
9	Total tax expenses	1.6	60.69
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	32.64	154.89
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	32.64	154.89
17	Other comprehensive income net of taxes	9.84	64.58
18	Total Comprehensive Income for the period	42.48	219.47
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		
	Paid-up equity share capital	966.1	966.1
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve	0	
23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	0.34	1.6
	Diluted earnings (loss) per share from continuing operations	0.34	1.6
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	0.34	1.6
	Diluted earnings (loss) per share from continuing and discontinued operations	0.34	1.6
24	Debt equity ratio		Textual Information(1)
25	Debt service coverage ratio		Textual Information(2)
26	Interest service coverage ratio		Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)	

Text Block	
Textual Information(4)	<div>1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.</div> <div>2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.</div> <div>3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 28/05/2025.</div> <div>4. The Figures for the Year ended 31 st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.</div> <div>5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.</div> <div>6. We would like to inform you that pursuant to sale of investment of its entire stake by Sandu Pharmaceuticals Limited in Sandu Phytoceuticals Private Limited-Wholly owned Non Material Subsidiary and therefore the company is not required to do consolidation of Financials for the Year ended 31/05/2025 and onwards.</div>

Statement of Asset and Liabilities		
Particulars	Year ended (dd-mm-yyyy)	
Date of start of reporting period	01-04-2024	
Date of end of reporting period	31-03-2025	
Whether results are audited or unaudited	Audited	
Nature of report standalone or consolidated	Standalone	
Assets		
1 Non-current assets		
Property, plant and equipment	846.56	
Capital work-in-progress	0	
Investment property	1122.42	
Goodwill	0	
Other intangible assets	2.39	
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
Non-current financial assets		
Non-current investments	0	
Trade receivables, non-current		
Loans, non-current	0	
Other non-current financial assets	5	
Total non-current financial assets	5	
Deferred tax assets (net)		
Other non-current assets	965.62	
Total non-current assets	2941.99	
2 Current assets		
Inventories	1414.86	
Current financial asset		
Current investments	0	
Trade receivables, current	475.73	
Cash and cash equivalents	130.39	
Bank balance other than cash and cash equivalents	134.91	
Loans, current	0	
Other current financial assets		
Total current financial assets	741.03	
Current tax assets (net)		
Other current assets	473.99	
Total current assets	2629.88	
3 Non-current assets classified as held for sale		
4 Regulatory deferral account debit balances and related deferred tax Assets		
Total assets	5571.87	
Total current assets	2629.88	
3 Non-current assets classified as held for sale		
4 Regulatory deferral account debit balances and related deferred tax Assets		
Total assets	5571.87	
Equity and liabilities		
1 Equity		
Equity attributable to owners of parent		
Equity share capital	966.1	
Other equity	3235.62	
Total equity attributable to owners of parent	4201.72	
Non controlling interest		
Total equity	4201.72	
2 Liabilities		
Non-current liabilities		
Non-current financial liabilities		
Borrowings, non-current	0	
Trade Payables, non-current		
(A) Total outstanding dues of micro enterprises and small enterprises		
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		
Total Trade payable		
Other non-current financial liabilities		
Total non-current financial liabilities	0	
Provisions, non-current	0	
Deferred tax liabilities (net)	119.64	
Deferred government grants, Non-current		
Other non-current liabilities	41.93	
Total non-current liabilities	161.57	
Current liabilities		
Current financial liabilities		
Borrowings, current	5.82	
Trade Payables, current		
(A) Total outstanding dues of micro enterprises and small enterprises	32.72	
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	416	
Total Trade payable	448.72	
Other current financial liabilities	25	
Total current financial liabilities	479.54	
Other current liabilities	190.69	
Provisions, current	538.35	
Current tax liabilities (Net)		
Deferred government grants, Current		
Total current liabilities	1208.58	
3 Liabilities directly associated with assets in disposal group classified as held for sale		
4 Regulatory deferral account credit balances and related deferred tax liability		
Total liabilities	1370.15	

	Total equity and liabilities	5571.87
Disclosure of notes on assets and liabilities	Textual Information(1)	

Other Comprehensive Income			
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Fair value changes of Investments	21.35	82.95
2	Remeasurement gain/(loss) on post employment defined benefit plans	-12.66	-12.66
	Total Amount of items that will not be reclassified to profit and loss	8.69	70.29
2	Income tax relating to items that will not be reclassified to profit or loss	-1.15	5.71
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	9.84	64.58

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	215.58
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	10.33
	Adjustments for decrease (increase) in inventories	-189.8
	Adjustments for decrease (increase) in trade receivables, current	-5.02
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-17.81
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	29.34
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	50.95
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	67.06
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	16.11
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	11.05
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-12.66
	Other adjustments for non-cash items	0.33
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-62.22
	Net cash flows from (used in) operations	153.36
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	58.32
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	95.04
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	93.8
	Proceeds from sales of investment property	152.89
	Purchase of investment property	150
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	191.9
	Purchase of other long-term assets	130
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	11.05
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	-17.96
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0

	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	41.42
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	77.29
	Interest paid	10.37
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	-46.24
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	30.84
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	30.84
	Cash and cash equivalents cash flow statement at beginning of period	99.55
	Cash and cash equivalents cash flow statement at end of period	130.39

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)																	
													Additional disclosure of related transaction relates to loans, interest on listed entity/subsidiary. These details are				
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness incurred to make or give loans, interest on corporate deposits, advances or investments		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost
1	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Private Limited	AADCS9226L	Entity in Which KMP/ Promoter/ Director are Interested	Purchase of goods or services		10000	Approved By Board and Shareholders. Transactions are within the sanctioned limits			1383.7	0	0			
2	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Private limited	AADCS9226L	Entity in Which KMP/ Promoter/ Director are Interested	Any other transaction	Royalty	10000	Approved By Board and Shareholders. Transactions are within the sanctioned limits			56.31	0	0			
3	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Private Limited	AADCS9226L	Entity in Which KMP/ Promoter/ Director are Interested	Sale of goods or services		10000	Approved By Board and Shareholders. Transactions are within the sanctioned limits			30.56	0	0			
4	Sandu Pharmaceuticals Limited	AAACS6291G	Mr. Umesh Bhaskar Sandu	ABWPS9336G	Remuneration of Managing Director	Remuneration		117.8	Approved By Board and Shareholders			54.9	0	0			
5	Sandu Pharmaceuticals Limited	AAACS6291G	Mr. Vijay Kajarekar	ADXP1740P	Remuneration of CFO	Remuneration			As per terms of the employment contract			3.32	0	0			
6	Sandu Pharmaceuticals Limited	AAACS6291G	Mrs. Pratika Mhambray	CTQPS2940K	Remuneration of CS	Remuneration			As per terms of the employment contract			3.8	0	0			
7	Sandu Pharmaceuticals Limited	AAACS6291G	Akshath Finvest & Properties Private Limited	AABCA2004Q	Promoter Group	Sale of goods or services		90	Approved by Audit Committee and are within the sanctioned limits			63.64	0	0			
8	Sandu Pharmaceuticals Limited	AAACS6291G	Mr. Shashank Bhaskar Sandu	ABWPS9337H	Non Executive Non Independent Director	Any other transaction	Sitting fees paid to Director		Approved by Board of Director			0.07	0	0			
9	Sandu Pharmaceuticals Limited	AAACS6291G	Shubhada Prabhakar Sandu	AAYPS6366F	Non Executive Non Independent Director	Any other transaction	Sitting fees paid to Director		Approved by Board of Director			0.03	0	0			
10	Sandu Pharmaceuticals Limited	AAACS6291G	Balram Vishwanathan	AADPV1404C	Chairman & Independent Director	Any other transaction	Sitting fees paid to Director		Approved by Board of Director			0.19	0	0			
11	Sandu Pharmaceuticals Limited	AAACS6291G	Ajit R Kantak	ADIPK8360Q	Non Executive Independent Director	Any other transaction	Sitting fees paid to Director		Approved by Board of Director			0.21	0	0			
12	Sandu Pharmaceuticals Limited	AAACS6291G	Vijay Kottapalli	BUQPK3745P	Non Executive Independent Director	Any other transaction	Sitting fees paid to Director		Approved by Board of Director			0.07	0	0			
13	Sandu Pharmaceuticals Limited	AAACS6291G	Jayshree Sandu	AGPPS8790L	Non Executive Non Independent Director	Any other transaction	Sitting fees paid to Director		Approved by Board of Director			0.07	0	0			
14	Sandu Pharmaceuticals Limited	AAACS6291G	Shashank Bhaskar Sandu	ABWPS9337H	Shareholder	Dividend paid			Approved by Board of Director/ Shareholder			10.95	0	0			
15	Sandu Pharmaceuticals Limited	AAACS6291G	Jayshree Sandu	AGPPS8790L	Shareholder	Dividend paid			Approved by Board of Director/ Shareholder			5.9	0	0			
16	Sandu Pharmaceuticals Limited	AAACS6291G	Umesh Bhaskar Sandu	ABWPS9336G	Shareholder	Dividend paid			Approved by Board of Director/ Shareholder			11.11	0	0			
17	Sandu Pharmaceuticals Limited	AAACS6291G	Minal Shashank Sandu	ABYPS5971R	Shareholder	Dividend paid			Approved by Board of Director/ Shareholder			0.49	0	0			
18	Sandu Pharmaceuticals Limited	AAACS6291G	Shubhada Prabhakar Sandu	AAYPS6366F	Shareholder	Dividend paid			Approved by Board of Director/ Shareholder			0.08	0	0			
19	Sandu Pharmaceuticals Limited	AAACS6291G	Geeta U Sandu	AGPPS8792J	Shareholder	Dividend paid			Approved by Board of Director/ Shareholder			0.68	0	0			
20	Sandu Pharmaceuticals Limited	AAACS6291G	Akshath Finvest & Properties Private Limited	AABCA2004Q	Shareholder	Dividend paid			Approved by Board of Director/ Shareholder			3.95	0	0			
Total value of transaction during the reporting period												1630.03					

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015:The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	M/S Dileep and Prithvi	Yes	31-10-2026

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	31-03-2021
Amount Raised	263.8
Report filed for Quarter ended	31-03-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	263.8	0	263.8	0	

Signatory Details	
Name of signatory	UMESH SANDU
Designation of person	Managing Director
Place	MUMBAI
Date	28-05-2025

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	28-02-2022
Amount Raised	138.05
Report filed for Quarter ended	31-03-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	138.05	0	134.52	0	Note: 1.The Company has unutilized money lying in the Escrow account as on 31st March 2025 of which FD is created in the name of the Company in Bank of Baroda for utilizing amount as and when required.

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (3)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	14-07-2022
Amount Raised	131.95
Report filed for Quarter ended	31-03-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	131.95	0	0	0	Note: 1.The Company has unutilized money lying in the Escrow account as on 31st March 2025 of which FD is created in the name of the Company in Bank of Baroda for utilizing amount as and when required.

